Back to the news

OncoDNA signs collaboration with BioClin Therapeutics for precision enrolment of lead drug Phase II clinical trial

Gosselies, Belgium – May 15, 2018

Using its precision enrolment services, OncoDNA will aid patient enrolment for BioClin Therapeutics’ FIERCE-21 and FIERCE-22 Phase II clinical programs for its lead candidate B-701

  • OncoDNA to support BioClin Therapeutics’ FIERCE-21 and FIERCE-22 clinical programs for B-701
  • Further demonstrates OncoDNA’s biopharma partnership strategy

OncoDNA (“OncoDNA or “the Company”), the healthcare technology company making precision medicine a reality, is pleased to announce that it has signed an agreement with BioClin Therapeutics.

Using its precision enrolment services, OncoDNA will aid patient enrolment for BioClin Therapeutics’ FIERCE-21 and FIERCE-22 Phase II clinical programs for its lead candidate B-701, a potential first-in-class human monoclonal antibody for patients with relapsed/refractory metastatic urothelial carcinoma with FGFR3 molecular alterations.

OncoDNA’s precision enrolment services team will engage with physicians across Europe to help identify FGFR3 mutation metastatic bladder cancer patients who may benefit from B-701. The Company’s enrolment team will inform these physicians about BioClin’s Phase II clinical trial and the potential for patient participation. The financial terms of the agreement have not been disclosed.

Jean-Pol Detiffe, Chief Executive Officer of OncoDNA, said: “This partnership with BioClin is another important step in our strategy to provide services to research and development companies that enable precision medicine. By supporting recruitment into BioClin’s trial, OncoDNA may ultimately support the creation of a new personalised treatment for metastatic bladder cancer. We look forward to working with BioClin and continuing to further the impact of precision medicine.”

About BioClin Therapeutics

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in the treatment of metastatic bladder cancer. The first clinical study is a Phase 1b/2 study of B-701 in combination with docetaxel. The study includes cohorts in which patients with FGFR3 mutation or fusion will be enrolled; patients will be administered B-701 plus docetaxel, or B-701 alone as monotherapy. The second study is evaluating the combination of B-701 and atezolizumab in mUC patients and will include those with overexpressed FGFR3 as well as those with FGFR3 mutation or fusion in their tumors. B-701 is also being tested in an on-going investigator sponsored study evaluating the combination of B-701 and pembrolizumab in mUC patients. For more information, please visit BioClin’s website: www.bioclintherapeutics.com

 

OncoDNA +32 (0) 71 18 35 00
Jean-Pol Detiffe, CEO
Pierre Flamant, CFO
Consilium Strategic Communications +44 (0)20 3709 5700
Amber Fennell, Sukaina Virji, Nicholas Brown, Hendrik Thys oncodna@consilium-comms.com